checkAd

    Amarin - The Science Of Lipid Therapy (Seite 12)

    eröffnet am 03.01.14 20:10:32 von
    neuester Beitrag 06.03.24 15:20:48 von
    Beiträge: 1.834
    ID: 1.190.027
    Aufrufe heute: 2
    Gesamt: 155.450
    Aktive User: 0


    Beitrag zu dieser Diskussion schreiben

     Durchsuchen
    • 1
    • 12
    • 184

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 24.06.22 10:39:52
      Beitrag Nr. 1.724 ()
      Antwort auf Beitrag Nr.: 71.794.592 von Magnetfeldfredy am 16.06.22 10:47:54Am 03.08.22 sollen ja wohl die Halbjahresergebnisse veröffentlicht werden - ich bin gespannt, was bis dahin passiert....
      Amarin | 1,885 €
      1 Antwort
      Avatar
      schrieb am 16.06.22 10:47:54
      Beitrag Nr. 1.723 ()
      Amrin
      Alex Denner macht Ernst, will die Looser auswechseln und selbst das Zügel in die Hand nehmen:

      Sarissa Capital Intends to Vote "Abstain" at the Amarin Annual Meeting

      Wed, June 15, 2022 at 10:50 PM
      In this article:

      AMRN
      +1.69%
      Watchlist

      Recommendation Rating
      Hold

      Sarissa intends to "Abstain" given ongoing engagement with Amarin to add shareholder representatives to the board

      GREENWICH, Conn., June 15, 2022--(BUSINESS WIRE)--Sarissa Capital Management LP ("Sarissa") today made the following statement on Amarin Corporation plc (NASDAQ: AMRN) regarding how it intends to vote at the upcoming Amarin annual meeting and the reasons therefor:

      Sarissa is a sophisticated, institutional investor with a long history of shareholder value creation in healthcare companies, including in the cardiovascular space, such as The Medicines Company. As Amarin's largest shareholder, we are frustrated by the performance of Amarin’s stock and believe Amarin should be better managed to maximize value for shareholders.

      Sarissa has discussed with the company our desire to add directors to the board. Although we are hopeful that the board will see the value that Sarissa brings as the largest shareholder and with a track record of creating shareholder value for cardiovascular disease focused companies, we are uncertain how our discussions regarding board representation will proceed. We note that despite a board refreshment process that began last October, the independent directors never proactively contacted Sarissa despite us being Amarin’s largest shareholder with a strong track record of value creation in cardiovascular care, such as The Medicines Company.

      Many shareholders have reached out asking how we intend to vote at the upcoming annual meeting.

      Given ongoing discussions, we intend to vote "ABSTAIN" on all matters at the annual meeting. We believe this reinforces our message that change is needed as we give the board the time to add shareholder representatives to the board.

      In addition, we intend to vote "ABSTAIN" at the annual meeting because even though such a vote will not impact the outcome of the upcoming election of directors, the United Kingdom, the jurisdiction in which Amarin is domiciled, contains laws and rights that protect the shareholder franchise even after the annual meeting. For example, under UK law and Amarin’s articles, shareholders, like Sarissa, who own at least 5% of the outstanding shares can call a special meeting of shareholders to remove and replace directors AT ANY TIME. Therefore, immediately after the annual meeting, we could call a special meeting and seek to remove and replace some or all of the Amarin directors with the affirmative vote of the holders of a majority of the outstanding shares.:D
      Amarin | 1,720 €
      2 Antworten
      Avatar
      schrieb am 14.06.22 10:47:30
      Beitrag Nr. 1.722 ()
      Amarin
      NICE empfiehlt VAZKEPA® (icosapent ethyl), um das kardiovaskuläre Risiko zu reduzieren
      13. Juni 2022
      NICE empfiehlt VAZKEPA® (icosapent ethyl), um das kardiovaskuläre Risiko zu reduzieren
      Icosapent ethyl wurde von NICE für die Verwendung im gesamten NHS in England und Wales empfohlen, um das kardiovaskuläre (CV) Risiko bei erwachsenen, mit Statin behandelten Patienten mit hohem CV-Risiko zu reduzieren.
      Amarin hat bekannt gegeben, dass das National Institute for Health and Care Excellence (NICE) die Verwendung von Icosapentethyl bei erwachsenen Statin-behandelten Patienten mit hohem kardiovaskulärem Risiko empfohlen hat, die erhöhte Triglyceride (≥150 mg / dl [≥ 1,7 mmol / L]), LDL-C-Spiegel > 1,04 mmol / L (und ≤ 2,60 mmol / L) und etablierte Herz-Kreislauf-Erkrankungen (CVD) haben.1,2 Die endgültige Prognose wird voraussichtlich für die 20heit vom Juli 2022.

      Dies ist die erste Behandlung in dieser Klasse, die von NICE zur Reduzierung des CV-Risikos empfohlen wird. Icosapentethyl ist ein neuer Wirkstoff, der eine hochgereinigte Omega-3-Fettsäure (Eicosapentaensäure >96%) enthält. Mit dieser Empfehlung hat icosapent ethyl das Potenzial, mehr als einer Million Menschen in England zu helfen, die ein hohes Risiko für ein nachfolgendes CV-Ereignis, wie z.B. einen zweiten Herzinfarkt, haben.1

      Mehr als sechs Millionen Menschen leben in England mit CVD und kosten den NHS jedes Jahr rund 7,4 Milliarden Pfund.3,4 Während aktuelle Therapien dazu beigetragen haben, das Risiko zukünftiger wichtiger CV-Ereignisse zu reduzieren, sterben jedes Jahr mehr als 137.000 Menschen an CVD.3 Ein erhebliches zukünftiges Risiko bleibt auch für die Patienten bestehen, da jeder Dritte innerhalb von sieben Jahren nach einer ersten Herzinfarktepisode ein nachfolgendes CV-Ereignis erleidet.5

      Innovative CV-Behandlung
      Icosapent-Ethyl stellt eine Innovation zur Verringerung dieses CV-Risikos bei Patienten in England dar. Die Evidenz aus der zulassungsrelevanten doppelblinden, randomisierten klinischen Phase-3-Studie REDUCE-IT zeigte, dass bei mehr als 8.000 Patienten über einen Zeitraum von durchschnittlich 4,9 Jahren die Behandlung mit Icosapentethyl im Vergleich zu Placebo zu einer relativen Verringerung des Risikos zukünftiger schwerer unerwünschter kardiovaskulärer Ereignisse um 25 % führte (eine Zusammensetzung aus CV-Tod, nicht tödlichem Myokardinfarkt, nicht tödlichem Schlaganfall, Koronare Revaskularisation oder Krankenhausaufenthalt bei instabiler Angina pectoris), eine absolute Risikoreduktion von 4,8% mit einer Zahl, die behandelt werden muss, um ein Ereignis von 21 zu vermeiden.6

      Dr. Derek Connolly, Consultant Interventional Cardiologist bei Sandwell & West Birmingham Hospitals NHS Trust, sagte: "CVD zählt zu den häufigsten Todesursachen in Großbritannien.3 Aktuelle Therapien wie Statine, die den LDL-C-Spiegel (Low-Density-Lipoprotein-Cholesterin) senken, haben große Erfolge bei der Verringerung der Todesfälle durch CV-Ereignisse erzielt, aber sie sind keine vollständige Lösung.

      Patienten mit einem gut kontrollierten LDL-C-Spiegel haben immer noch ein Risiko für ein CV-Ereignis, und andere Faktoren, wie erhöhte Bluttriglyceride, sollten als Risikomarker für zukünftige Ereignisse in Betracht gezogen werden.

      Die REDUCE-IT-Studie zeigte, dass es mit icosapent ethyl möglich ist, dieses Risiko weiter zu reduzieren und zukünftige CV-Ereignisse zu verhindern."

      Die am häufigsten berichteten Nebenwirkungen in der REDUCE-IT-Studie im Zusammenhang mit Icosapentethyl waren Blutungen (11,8 %), periphere Ödeme (7,8 %), Vorhofflimmern (5,8 %), Verstopfung (5,4 %), Muskel-Skelett-Schmerzen (4,3 %), Gicht (4,3 %) und Hautausschlag (3,0 %).2

      Amarin's Laurent Abuaf, Senior Vice President & President of Europe, sagte: "VAZKEPA bietet eine wichtige wissenschaftliche Innovation für Patienten mit CVD, und die Ergebnisse der REDUCE-IT-Studie zeigen die Vorteile ihrer Verwendung zur Optimierung der Ergebnisse von Patienten mit hohem Risiko für CV-Ereignisse, zusätzlich zu Behandlungen für traditionelle Risikofaktoren.

      Die Empfehlung von NICE wird dazu beitragen, das Risiko von CV-Ereignissen bei einer signifikanten Anzahl von Patienten in England und Wales zu reduzieren, und wir verpflichten uns, mit allen relevanten Interessengruppen im NHS zusammenzuarbeiten, um Patienten mit CVD diese wichtige neue Behandlungsoption anzubieten. "

      Referenzen
      Nationales Institut für Gesundheit und Pflege Exzellenz. Endgültige Bewertungsentscheidung: Icosapentethyl mit Statintherapie zur Verringerung des Risikos kardiovaskulärer Ereignisse bei Menschen mit erhöhten Triglyceriden [Internet]. [London]: NIZZA; 2022. https://www.nice.org.uk/guidance/gid-ta10736/documents/html-…
      VAZKEPA (icosapent ethyl) Zusammenfassung der merkmale des arzneimittels (April 2022) https://www.medicines.org.uk/emc/product/12964/smpc#gref. Abgerufen im Juni 2022.
      British Heart Foundation. UK Factsheet Januar 2022. https://www.bhf.org.uk/-/media/files/research/heart-statisti… – UK-Factsheet.pdf. Abgerufen im Juni 2022.
      Öffentliche Gesundheit England. Gesundheit ist wichtig: Prävention von Herz-Kreislauf-Erkrankungen. https://www.gov.uk/government/publications/health-matters-pr… Abgerufen im Juni 2022.
      Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe wurde der Statintherapie nach akuten Koronarsyndromen zugesetzt. N Engl J Med. 2015;372(25):2387-97.
      Bhatt DL, Steg PG, Miller M et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019; 380(1):11-22.
      Amarin | 1,630 €
      Avatar
      schrieb am 12.06.22 19:22:22
      Beitrag Nr. 1.721 ()
      Ich hab schon nachgelegt. Das Teil wird laufen.
      Amarin | 1,800 $
      Avatar
      schrieb am 12.06.22 15:53:07
      Beitrag Nr. 1.720 ()
      Antwort auf Beitrag Nr.: 71.760.083 von Magnetfeldfredy am 11.06.22 17:22:04Schöne News
      Könnte man eigentlich noch mal nachlegen 🤔🤪
      Amarin | 1,800 $

      Trading Spotlight

      Anzeige
      Rallye II. – Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…mehr zur Aktie »
      Avatar
      schrieb am 11.06.22 17:22:04
      Beitrag Nr. 1.719 ()
      Amarin
      Englands renommierte Zeitung publiziert Amarin Riesenerfolg, big pharma läßt Amarin die Drecksarbeit mit Erstattung machen und schnappt sich dann die Firma, wenigstens wird uns in Europa kein Generika 10 Jahre in die Quere kommen:

      The Telegraph
      New heart attack drug to be offered to patients who need more than just statins
      Laura Donnelly
      Fri, June 10, 2022 at 7:45 PM·3 min read
      Heart attack
      Heart attack

      Nearly 500,000 people for whom statins are not enough will be given extra drugs to cut the risk of heart attacks, following new NHS guidance.

      Around one in three people who are already on statins because of high cholesterol levels also have raised blood fats, which put them in greater danger.

      The draft guidance from the National Institute of Health and Care Excellence (Nice) means that, for the first time, many such patients will be offered tailored medication.

      Studies have found that icosapent ethyl, the first licensed treatment for the condition, can cut the risk of heart attacks and strokes by more than a quarter.

      The new guidance means it can be offered to about 425,000 people on statins who have raised levels of triglycerides.

      The recommendation in favour of the treatment, also called Vazkepa and made by Amarin, will apply only to patients whose “bad” cholesterol levels - low-density lipoprotein cholesterol - are controlled.

      Until now, there have been no medicines for people at risk of cardiovascular events who have raised levels of triglycerides despite taking statins or other anti-cholesterol drugs.
      Final consultation with patients over drug

      NHS England estimates that between 25 per cent and 35 per cent of the eight million people in the UK taking statins have elevated levels of the blood fat.

      Triglycerides are our main source of energy and essential for good health. However, too much in your blood can indicate a higher risk of cardiovascular events. It can also cause damage to arteries in organs such as the brain, heart, kidneys and eyes.

      Helen Knight, interim director of medicines evaluation at Nice, said: “Icosapent ethyl is the first licensed treatment of its kind for people who are at risk of heart attacks and strokes despite well-controlled LDL cholesterol because they have raised blood fats. And although lifestyle changes, including diet and exercise, can help to reduce their risk, these may not work for everyone.

      “We have worked closely with the company to identify the population most likely to gain the greatest benefit from icosapent ethyl, striking a balance between effectiveness and the best use of public funding, delivering maximum value to the taxpayer.”

      Final guidance is expected next month, following a consultation with patients and professional groups.

      Heart and circulatory disease are one of the biggest killers in the UK, causing one quarter of all deaths. Four million men and about 3.6 million women suffer from heart disease.

      Icosapent ethyl, which is given twice daily, is thought to reduce very low-density lipoprotein triglyceride synthesis and secretion in the liver, as well as enhance triglyceride clearance. The drug costs the NHS around £1.20 a pill, while statins cost pennies.

      It follows warnings that heart attack deaths soared by one-fifth during the pandemic, according to a major review that warns of the huge “global collateral damage” of Covid and lockdowns.

      An analysis of nearly 200 studies by researchers from Leeds University found deaths among people hospitalised due to severe heart problems increased by 17 per cent in two years. Patients also waited for more than an hour longer than usual for cardiac and heart attack callouts between December 2019 to December 2021.

      Across the world, the number of heart operations carried out fell by 34 per cent. It follows warnings that many people kept away from GPs and hospitals or struggled to access services during the pandemic.
      Amarin | 1,800 $
      1 Antwort
      Avatar
      schrieb am 10.06.22 20:07:22
      Beitrag Nr. 1.718 ()
      "Risiko lässt sich um bis zu 61 Prozent senken
      Alle Teilnehmer erhielten alle drei Monate Kontrollanrufe und wurden jedes Jahr untersucht.

      81 Teilnehmende entwickelten im Nachbeobachtungszeitraum eine Krebserkrankung. Als effektivste Krebsvorbeugung erwies sich die Dreier-Kombination aus Vitamin D, Omega-3-Fettsäuren und einem leichten Trainingsprogramm. Dieser Maßnahmen-Mix senkte das Krebsrisiko um 61 Prozent.

      Wurden nur zwei Maßnahmen angewandt, ergab sich eine Risiko-Absenkung zwischen 44 und 48 Prozent. Nur eine Maßnahme zeigte eine Wirkung von 30 bis 34 Prozent.

      Geringe Kosten, große Wirkung
      Studienleiterin Heike A. Bischoff-Ferrari, Professorin für Geriatrie und Altersforschung an der Universität Zürich, erläutert in der Pressemitteilung: "Obgleich unsere Ergebnisse in einer längerfristigen und noch größeren Studie repliziert werden sollten, qualifizieren die drei Maßnahmen anhand ihrer hohen Sicherheit und den geringen Kosten bereits heute, um die hohe Last von Krebserkrankungen bei älteren Erwachsenen zu reduzieren."
      https://www.t-online.de/gesundheit/krankheiten-symptome/id_9…

      Tja, woher nur dieses Omega-3-Fettsäuren-Gebräu nehmen? Jeden Tag zwischen 300-500 g Fisch essen (lachs, Makrele)? Oder einen Teelöffel Leinöl? Oder ... 🤔😉
      Amarin | 1,760 $
      Avatar
      schrieb am 10.06.22 13:19:31
      Beitrag Nr. 1.717 ()
      Amarin
      Das Management liefert endlich und mit 10 Jahre Exklusivität ist hier ein echter Turnaroundkandidat
      am Markt zu Spottpreisen erhältlich, Amarin wird bald zweistellig übernommen!

      Nochmals und weils so schön und wichtig ist, besonders der monatliche Preis ist zukunftsweisend für die anderen europäischen Länder:

      Amarin: UK's NICE recommends reimbursement, use of VAZKEPA 06:03 AMRN Amarin announces that the UK's National Institute for Health and Care Excellence is recommending icosapent ethyl, marketed under the brand name VAZKEPA, for reimbursement and use across the National Health Service in England and Wales to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk who have elevated triglycerides, LDL-C levels greater than1.04 mmol/L, and established cardiovascular disease, at a price of GBP 144.21 per 120 soft capsules.:eek::lick:

      Read more at:
      https://thefly.com/n.php?id=3529139
      Amarin | 1,675 €
      Avatar
      schrieb am 10.06.22 12:57:30
      Beitrag Nr. 1.716 ()
      Amarin
      Top Meldung für Europa, NICE erstattet für England:eek::D und Wales für EUR 170 im Monat:lick:, da wird sich Pfizer bald freuen:



      Amarin Receives Positive Recommendation from United Kingdom’s (UK) National Institute for Health and Care Excellence (NICE) for Reimbursement of VAZKEPA® (icosapent ethyl)

      AMRN
      -5.82%
      Amarin Corporation plc
      Fri, June 10, 2022, 12:00 PM
      In this article:

      AMRN
      -5.82%
      Watchlist

      Watchlist
      Recommendation Rating
      Hold
      Amarin Corporation plc
      Amarin Corporation plc
      UK’s NICE issued its draft Final Appraisal Document (FAD) recommending the use of VAZKEPA® (icosapent ethyl) in England and Wales to reduce the risk of cardiovascular (CV) events in adult statin-treated patients at high CV risk who have elevated triglycerides (≥150 mg/dL [≥ 1.7 mmol/L]) and established cardiovascular disease (eCVD) 1,2

      Positive reimbursement recommendation follows the recent national reimbursement for VAZKEPA in Sweden and marks another major milestone in the company’s European growth strategy

      DUBLIN, Ireland and BRIDGEWATER, N.J., June 10, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announces that the UK’s National Institute for Health and Care Excellence (NICE) is recommending icosapent ethyl (marketed under the brand name VAZKEPA®) for reimbursement and use across the National Health Service (NHS) in England and Wales to reduce the risk of cardiovascular (CV) events in adult statin-treated patients at high cardiovascular risk who have elevated triglycerides (≥150 mg/dL [≥ 1.7 mmol/L]), LDL-C levels >1.04 mmol/L (and ≤ 2.60 mmol/L) and established cardiovascular disease (eCVD), at a price of £144.21 per 120 soft capsules (i.e. 30-day supply; equivalent of approximately 170 EUR or 181 USD*).1,2

      “We are extremely pleased with today’s positive recommendation by NICE,” said Karim Mikhail, president and chief executive officer. “This is another important step forward in successfully executing our European growth strategy, and considering that the UK has historically served as a reference market with regard to Health Technology Assessments, it is a major step toward unlocking the company’s multi-billion-dollar revenue opportunity outside of the U.S.**”

      Cardiovascular disease ranks as one of the UK’s leading causes of death3. More than six million people live with cardiovascular disease in England, costing the NHS around £7.4 billion each year3,4. VAZKEPA represents an important scientific innovation for reducing cardiovascular risk in eligible patients across England and Wales, supported by the clinical data from the landmark REDUCE-IT® cardiovascular outcome study5.

      The Final Appraisal Document (FAD) is part of NICE’s Health Technology Appraisal (HTA) process aimed at making recommendations on both the clinical and cost effectiveness of medicines and treatments in England to help ensure that the NHS uses its resources fairly and cost-effectively. Today’s FAD represents the NICE appraisal committee’s draft final guidance related to the use of icosapent ethyl within the NHS in England. NICE’s final guidance is expected to be published on the 13th of July 2022, after which all local NHS formularies are expected to make the product available within 3 months. Based on a collaboration with the Welsh Government and the All Wales Medicines Strategy Group (AWMSG), the final NICE guidances will also apply to Wales and be implemented across the NHS in Wales.

      “This positive recommendation is the outcome of many months of constructive scientific discussions with multiple stakeholders and a detailed systematic review of clinical and economic evidence,” commented Laurent Abuaf, senior vice president and president Amarin Europe. “Following Sweden, this is now the second Health Technology Assessment in Europe that recognizes the potential value of VAZKEPA for strengthening cardiovascular care in England and Wales, following a very rigorous clinical and economic evaluation process. We look forward to working with all relevant stakeholders in the NHS to offer this important new treatment option to eligible cardiovascular patients across these countries in the UK.”

      In parallel, Amarin continues to progress well with its reimbursement discussions in the other European markets and remains on track to receive pricing decisions in up to eight countries with plans to launch VAZKEPA in up to six European countries this year.

      *Based on exchange rate of EUR and USD as of the date of this release.
      ** U.S. Dollar

      About Amarin®
      Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our scientific research foundation to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to rethinking cardiovascular risk through the advancement of scientific understanding of the impact on society of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management.

      About VASCEPA®/VAZKEPA® (icosapent ethyl) Capsules

      VASCEPA capsules are the first prescription treatment approved by the U.S. Food and Drug Administration (FDA) comprised solely of the active ingredient, icosapent ethyl, a unique form of eicosapentaenoic acid. VASCEPA was launched in the United States in January 2020 as the first and only drug approved by the U.S. FDA for treatment of the studied high-risk patients with persistent cardiovascular risk after statin therapy. VASCEPA was initially launched in the United States in 2013 based on the drug’s initial FDA approved indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed over 18 million times. VASCEPA is covered by most major medical insurance plans. In addition to the United States, icosapent ethyl is approved and sold in Canada, Lebanon, Germany and the United Arab Emirates. In Europe, in March 2021 marketing authorization was granted to icosapent ethyl in the European Union for the reduction of risk of cardiovascular events in patients at high cardiovascular risk, under the brand name VAZKEPA. In April 2021 marketing authorization for VAZKEPA (icosapent ethyl) was granted in Great Britain. The Great Britain Marketing Authorization for VAZKEPA applies to England, Scotland and Wales.
      Amarin | 1,675 €
      Avatar
      schrieb am 06.06.22 15:26:19
      Beitrag Nr. 1.715 ()
      Amarin
      Neuer CFO, Alex Denner die Biotech Verkauslegende will ins BOD:eek::D, Kostenreduktion, Nachtigall ich hör Dir trapsen, die Braut wird schön gemacht und Novartis wird meine Meinung nach kaufen, weltweit mehrere tausende Reps werden Vascepa zum Megablockbuster weltweit machen, KZ US Dollar 15:

      Amarin Announces Comprehensive Cost Reduction Plan to Address Market Dynamics in U.S. Business

      Amarin Corporation plc
      Mon, June 6, 2022 at 2:30 PM
      In this article:

      AMRN
      +15.07%
      Watchlist

      Significant Event | 3dyahoo plus badge
      Sarissa Capital Management Says Intends To Seek Representation On Amarin Corp PLC’S Board - SEC Filing

      Amarin Corporation plc
      Amarin Corporation plc

      -- Company Expects to Achieve Approximately $100 Million in Cost Savings Over the Next 12 Months* While Continuing to Invest in European Launches and Global Expansion --

      -- Reduces U.S. Commercial Organization by Ninety Percent of Pre-Pandemic / Pre-Generic Competition Levels --

      -- Creates Core Focused U.S. Commercial Team to Support Branded VASCEPA Revenues --

      -- Actions Optimize Operations While Maintaining Positive U.S. Contribution Margin to Support Company’s Next Steps --

      DUBLIN, Ireland and BRIDGEWATER, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced important and critical actions including a comprehensive cost and organizational restructuring plan to address current shifts within the Company’s U.S. business. The Company expects these actions will reduce operating costs by approximately $100 million over the next 12 months* and enable Amarin to maintain a positive contribution margin in the U.S. while continuing to invest in its imminent European market launches and global expansion for VASCEPA/VAZKEPA.

      “Our management team, with the guidance of our Board, conducted a comprehensive review of the business to ensure we are addressing the realities within our U.S. business while we focus on our global growth opportunities with efficiency and discipline,” said Karim Mikhail, Amarin’s president and chief executive officer. “While we continue to see value in branded VASCEPA in the U.S., the current operating landscape remains challenging with uncertainty related to future revenue from the U.S. business. As a result, today we are taking critical, proactive steps to reduce our U.S. commercial team by approximately 90% of our pre-pandemic and pre-generic competition levels. These reductions are necessary as we invest in our European launches while maintaining a strong, core U.S. Commercial team to support branded VASCEPA revenues in the U.S. These proactive steps also allow us to maintain a positive contribution margin for the U.S. business and continue our investments in other markets and our Fixed-Dose Combination (FDC) program to ensure we are positioned for a stronger future as we execute our European and global expansion plans.”

      Mr. Mikhail added, “We have completely reshaped our investment plan for the future. We have tremendous confidence in our multi-billion dollar revenue opportunity for VASCEPA/VAZKEPA globally where we remain on track to launch in six markets and receive up to eight reimbursement decisions this year. These comprehensive actions will enable us to better serve patients while creating value for shareholders over the long-term.”

      The Company will reduce its total operational expenditure by approximately $100 million over the next 12 months* while continuing its investments in European expansion. The Company’s cost reduction plan includes:

      U.S. workforce reduction: The majority of the cost savings will result from a significant workforce reduction across the Company’s U.S. field force and corporate positions. Amarin will reduce its U.S. commercial team by approximately 65% from current levels and approximately 90% of pre-pandemic and pre-generic competition levels, resulting in a core team able to support branded VASCEPA revenues in the U.S. In total, these actions will result in a reduction of the total company employee base by over 40% from current levels.

      Streamlined operational expenditures: Includes reductions and reallocations in overall selling, general and administrative (SG&A) expenses as well as savings related to refining the Company’s R&D strategy to a more focused, stepwise approach for its FDC program.

      Mr. Mikhail concluded, “We value the tremendous contributions of our colleagues – whose dedication to our mission has helped build this Company and enabled us to launch an innovative product that has improved cardiovascular health for millions of patients. These changes, while difficult, are necessary to support our ability to continue bringing VASCEPA/VAZKEPA to patients around the world.”

      *Compared to 2021 full year GAAP operating expenses and excludes restructuring charges.
      Amarin | 1,700 €
      • 1
      • 12
      • 184
       DurchsuchenBeitrag schreiben


      Investoren beobachten auch:

      WertpapierPerf. %
      +0,48
      -0,95
      +0,39
      +0,29
      +0,09
      -0,05
      +0,14
      -0,79
      -0,64
      -4,82
      25.03.24 · globenewswire · Amarin
      29.02.24 · globenewswire · Amarin
      15.02.24 · globenewswire · Amarin
      23.01.24 · wO Chartvergleich · Canadian Imperial Bank of Commerce
      22.01.24 · globenewswire · Amarin
      10.01.24 · globenewswire · Amarin
      12.11.23 · globenewswire · Amarin
      01.11.23 · globenewswire · Amarin
      31.10.23 · globenewswire · Amarin
      26.10.23 · globenewswire · Amarin
      Amarin - The Science Of Lipid Therapy